Ats Medical, Inc. (ATSI) rated Mkt Outperform with price target $4 by Rodman & Renshaw
Rodman & Renshaw rated Mkt Outperform Ats Medical, Inc. (NASDAQ: ATSI) on 08/05/2008. Previously Rodman & Renshaw rated Mkt Outperform Ats Medical, Inc. (NASDAQ:
ATSI) on 02/28/2008., when the stock price was $1.87. Since then, Ats Medical, Inc. has gained 72.73% as of 08/20/2010's recent price of $3.23. If you would have followed the previous Rodman & Renshaw's recommendation on ATSI, you would have gained 72.72% of your investment in 904 days.
ATS Medical, Inc. (ATS) develops, manufactures and markets medical devices for the treatment of structural heart disease. Product offerings include devices for the treatment of structural heart disease with a focus on heart valve therapy and the surgical treatment of cardiac arrhythmias. Heart valve therapy products consist of mechanical and tissue heart valves and heart valve repair products. Surgical arrhythmia therapy products consist of cryotherapy products for the ablation of cardiac arrhythmias. During the year ended December 31, 2008, sales of mechanical heart valves represented approximately 65% of the Company?s revenue.
Rodman & Renshaw
is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.